Key2brain Ab

Key2Brain is a Swedish biotechnology company dedicated to developing next generation brain targeting therapies utilizing its proprietary blood-brain barrier-crossing technology. The technology enables efficient brain uptake and broad distribution into the brain and can be integrated into a wide range of therapeutic molecules. The pipeline is being developed internally and in partnerships where Key2Brain’s team leverages extensive industry experience in biologics and brain-targeting drugs, accelerating the translation from discovery to the clinic.